JP2013510076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510076A5 JP2013510076A5 JP2012528790A JP2012528790A JP2013510076A5 JP 2013510076 A5 JP2013510076 A5 JP 2013510076A5 JP 2012528790 A JP2012528790 A JP 2012528790A JP 2012528790 A JP2012528790 A JP 2012528790A JP 2013510076 A5 JP2013510076 A5 JP 2013510076A5
- Authority
- JP
- Japan
- Prior art keywords
- animal
- composition
- cognitive function
- melatonin
- carotenoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 10
- 230000003920 cognitive function Effects 0.000 claims 8
- 229960003987 Melatonin Drugs 0.000 claims 7
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 7
- 150000001747 carotenoids Chemical class 0.000 claims 6
- 235000019529 tetraterpenoid Nutrition 0.000 claims 6
- KBPHJBAIARWVSC-TWGKZGRNSA-N (3R,3'R,6'R)-β,ε-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-TWGKZGRNSA-N 0.000 claims 4
- 229960005375 Lutein Drugs 0.000 claims 4
- 235000012680 lutein Nutrition 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 235000008210 xanthophylls Nutrition 0.000 claims 3
- MQZIGYBFDRPAKN-QISQUURKSA-N 6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-(4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC=1C(=O)C(O)CC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)C(O)CC1(C)C MQZIGYBFDRPAKN-QISQUURKSA-N 0.000 claims 2
- 239000004212 Cryptoxanthin Substances 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 235000013793 astaxanthin Nutrition 0.000 claims 2
- 239000001168 astaxanthin Substances 0.000 claims 2
- 229940022405 astaxanthin Drugs 0.000 claims 2
- 230000003542 behavioural Effects 0.000 claims 2
- 230000019771 cognition Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N (1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 claims 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims 1
- PGYAYSRVSAJXTE-FTLOKQSXSA-N 9'-cis-neoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O PGYAYSRVSAJXTE-FTLOKQSXSA-N 0.000 claims 1
- 229940062527 Alendronate Drugs 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 claims 1
- 229960004015 Calcitonin Drugs 0.000 claims 1
- 102400000113 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 1
- 229960003980 Galantamine Drugs 0.000 claims 1
- 229940068052 Ginkgo biloba extract Drugs 0.000 claims 1
- 239000009429 Ginkgo biloba extract Substances 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- KBPHJBAIARWVSC-NRHWGSPPSA-N Lutein Natural products O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](O)CC=2C)\C)/C)\C)/C)C(C)(C)C1 KBPHJBAIARWVSC-NRHWGSPPSA-N 0.000 claims 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 claims 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004622 Raloxifene Drugs 0.000 claims 1
- 229940089617 Risedronate Drugs 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 claims 1
- 239000004213 Violaxanthin Substances 0.000 claims 1
- SZCBXWMUOPQSOX-WVJDLNGLSA-N Violaxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-WVJDLNGLSA-N 0.000 claims 1
- SZCBXWMUOPQSOX-AWKIANPTSA-N Violaxanthin Natural products O[C@H]1CC(C)(C)[C@@]2(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@]34C(C)(C)C[C@H](O)C[C@@]3(C)O4)\C)/C)\C)/C)[C@](C)(O2)C1 SZCBXWMUOPQSOX-AWKIANPTSA-N 0.000 claims 1
- JKQXZKUSFCKOGQ-PQJNXSRMSA-N Zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-PQJNXSRMSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- 229960003642 nicergoline Drugs 0.000 claims 1
- 239000003075 phytoestrogen Substances 0.000 claims 1
- 229960002934 propentofylline Drugs 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960000744 vinpocetine Drugs 0.000 claims 1
- 235000019245 violaxanthin Nutrition 0.000 claims 1
- 235000010930 zeaxanthin Nutrition 0.000 claims 1
- 239000001775 zeaxanthin Substances 0.000 claims 1
- 229940043269 zeaxanthin Drugs 0.000 claims 1
Claims (20)
- 動物の認知機能を向上させるのに適した組成物であって、メラトニン及び少なくとも1種のカロテノイドを、該動物の認知機能を向上させるのに有効な量含む組成物。
- 約0.001〜約100mg/kgのメラトニン及び約0.001〜約50mg/kgの少なくとも1種のカロテノイドを含む、請求項1に記載の組成物。
- 亜鉛を、認知機能を向上させるのに有効な量さらに含む、請求項1に記載の組成物。
- 約0.1〜400mg/kgの亜鉛を含む、請求項3に記載の組成物。
- 動物の認知機能を向上させるための方法であって、メラトニン及び少なくとも1種のカロテノイドを含む組成物を、該動物の認知機能を向上させるのに有効な量該動物に投与するステップを含み、前記動物がヒトを含まない、方法。
- 前記メラトニンは合成メラトニンである、請求項5に記載の方法。
- 前記カロテノイドはキサントフィルである、請求項5に記載の方法。
- 前記キサントフィルは、アスタキサンチン、ルテイン、ゼアキサンチン、ネオキサンチン、ビオラキサンチン、α−クリプトキサンチン及びβ−クリプトキサンチンからなる群より選択される、請求項7に記載の方法。
- 前記キサントフィルはアスタキサンチンである、請求項7に記載の方法。
- 前記動物は加齢動物である、請求項5に記載の方法。
- 前記動物は、加齢の過程又は外傷若しくは疾患により引き起こされる認知機能の低下が起こりやすいか起きている動物である、請求項5に記載の方法。
- 前記組成物は、約0.001〜約100mg/kgのメラトニン及び約0.001〜約50mg/kgの少なくとも1種のカロテノイドを含む、請求項5に記載の方法。
- 前記組成物は、亜鉛を、認知機能を向上させるのに有効な量さらに含む、請求項5に記載の方法。
- 前記組成物は約0.1〜400mg/kgの亜鉛を含む、請求項13に記載の方法。
- 前記組成物は、少なくとも1種の認知関連薬物と併せて、認知機能を向上させるのに有効な量該動物に投与される、請求項5に記載の方法。
- 前記認知関連薬物は、セレギリン、ニセルゴリン、ホスファチジルセリン、プロペントフィリン、ガランタミン、ビンポセチン、ドネペジル、ギンクゴ・ビロバ抽出物、ビスホソホネート、ラロキシフェン、エストロゲン、フィトエストロゲン、カルシトニン、リセドロネート又はアレンドロネートの少なくとも1種である、請求項15に記載の方法。
- 前記動物は加齢動物である、請求項5に記載の方法。
- 前記動物は、加齢性認知障害に関連する表現型を有する、請求項17に記載の方法。
- 前記表現型は、該表現型を有しない対照動物と比較して、想起能力の低下、短期記憶喪失、学習速度の低下、学習能力の低下、問題解決能力の低下、注意持続時間の低下、錯乱の増加又は認知症の少なくとも1つを含む、請求項18に記載の方法。
- 動物の加齢性の行動変化を抑制又は予防する方法であって、メラトニン及び少なくとも1種のカロテノイドを、該動物の加齢性の行動変化を抑制又は予防するのに有効な量該動物に投与するステップを含み、前記動物がヒトを含まない、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27640209P | 2009-09-11 | 2009-09-11 | |
US61/276,402 | 2009-09-11 | ||
PCT/US2010/002440 WO2011031304A2 (en) | 2009-09-11 | 2010-09-02 | Compositions and methods for enhancing cognitive and related functions in animals |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013510076A JP2013510076A (ja) | 2013-03-21 |
JP2013510076A5 true JP2013510076A5 (ja) | 2013-10-17 |
JP5863656B2 JP5863656B2 (ja) | 2016-02-16 |
Family
ID=43732999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012528790A Expired - Fee Related JP5863656B2 (ja) | 2009-09-11 | 2010-09-02 | 動物の認知機能及び認知関連機能を向上させるための組成物及び方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120171303A1 (ja) |
EP (1) | EP2464350B1 (ja) |
JP (1) | JP5863656B2 (ja) |
CN (1) | CN103533933A (ja) |
AU (1) | AU2010293065B2 (ja) |
BR (1) | BR112012005540A2 (ja) |
CA (1) | CA2773523A1 (ja) |
ES (1) | ES2593880T3 (ja) |
MX (1) | MX2012002996A (ja) |
RU (1) | RU2569743C2 (ja) |
WO (1) | WO2011031304A2 (ja) |
ZA (1) | ZA201202561B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012078317A1 (en) * | 2010-12-07 | 2012-06-14 | Nestec S. A. | Methods and compositions useful for promoting sleep in animals |
WO2016111265A1 (ja) | 2015-01-08 | 2016-07-14 | 江崎グリコ株式会社 | 抗酸化剤及び抗酸化/uvケア化粧料 |
CN104886574B (zh) * | 2015-06-04 | 2017-06-13 | 南京贝杉国际贸易有限公司 | 一种改善睡眠保护视力的中老年保健食品及其制备方法 |
CA2912611C (en) | 2015-11-18 | 2024-01-30 | Fb Health S.P.A. | Homotaurine compounds, compositions and formulations for animal care |
US11478011B2 (en) | 2015-12-14 | 2022-10-25 | Societe Des Produits Nestle S.A. | Nutritional compositions and infant formula for promoting de novo myealination |
PT3389407T (pt) * | 2015-12-14 | 2024-01-19 | Nestle Sa | Composição nutricional e fórmula para lactentes para promover mielinização de novo |
JP2017218424A (ja) | 2016-06-08 | 2017-12-14 | アスタリール株式会社 | 認知機能向上のための運動療法において使用するための、カロテノイドを含む認知機能向上組成物 |
SG10201900604TA (en) * | 2019-01-23 | 2020-08-28 | Agency For Science Technology And Research Astarstar | Pre-natal beta-cryptoxanthin benefits children |
CN109892247B (zh) * | 2019-04-19 | 2023-08-18 | 桂林医学院 | 一种猫参与的检测大鼠认知功能的实验装置 |
JP6861264B1 (ja) * | 2019-11-19 | 2021-04-21 | 慶昌 木島 | 組成物 |
CN111838321A (zh) * | 2020-08-18 | 2020-10-30 | 青岛大学 | 一种含叶黄素和益生元的老年营养包及其制备方法 |
KR102517992B1 (ko) * | 2022-05-26 | 2023-04-05 | 주식회사 에이엘 네트웍스 | 인지장애 및 뇌기능 개선을 위한 펫푸드 조성물 및 이의 제조 방법 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
PT1283038E (pt) | 2000-05-16 | 2008-10-23 | Suntory Ltd | Composições normalizadoras do ritmo circadiano |
US20020120001A1 (en) * | 2000-10-13 | 2002-08-29 | Ashni Naturaceuticals, Inc. | Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect |
US6821997B1 (en) * | 2000-10-16 | 2004-11-23 | Victorio C. Rodriguez | Therapeutic and prophylactic treatment of aging and disorders of aging in humans |
US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
WO2004011423A2 (en) * | 2002-07-29 | 2004-02-05 | Hawaii Biotech, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
CA2527957A1 (en) * | 2003-06-02 | 2005-01-06 | Ohio University | Use of genes differentially expressed during aging of liver for treatment and diagnosis |
IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
WO2005037215A2 (en) * | 2003-10-14 | 2005-04-28 | Massachusetts Institute Of Technology | Compositions and methods for enhancing cognitive function and synaptic plasticity |
US20060039954A1 (en) * | 2003-12-23 | 2006-02-23 | Gierhart Dennis L | Ocular formulations with neuroprotectants to reduce Alzheimer and neurotoxic risks created by large zinc dosages |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
IL162288A0 (en) * | 2004-06-01 | 2005-11-20 | Future Products Man S A | Compositions and methods for treating neurodegenerative disorders |
CN101277739B (zh) | 2005-09-30 | 2013-01-02 | 雀巢技术公司 | 用于增强认知功能的方法和组合物 |
JP2007126455A (ja) * | 2005-10-07 | 2007-05-24 | Fuji Chem Ind Co Ltd | 脳機能障害の改善剤 |
JP4993900B2 (ja) * | 2005-11-28 | 2012-08-08 | 国立大学法人 東京医科歯科大学 | 記憶障害抑制剤 |
CA2632550C (en) | 2005-12-15 | 2017-07-25 | Nestec S.A. | Medium chain triglycerides for preserving cognitive function |
CA2675230A1 (en) * | 2006-01-10 | 2008-07-26 | Pipex, Inc. | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
WO2007088046A2 (en) * | 2006-02-01 | 2007-08-09 | Nestec S.A. | Nutritional system and methods for increasing longevity |
EP2005951A2 (en) * | 2006-03-29 | 2008-12-24 | Kaneka Corporation | Agent for improving nervous system cell functions |
US7897637B2 (en) * | 2006-07-19 | 2011-03-01 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
WO2008083204A2 (en) | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
US20100076091A1 (en) * | 2007-02-14 | 2010-03-25 | Tohoku University | Composition and method for suppressing lipooxidation of erythrocyte |
CN101820754A (zh) | 2007-10-04 | 2010-09-01 | 雀巢产品技术援助有限公司 | 用于增强认知功能的组合物与方法 |
CA2994586C (en) | 2008-01-04 | 2020-07-21 | Nestec S.A. | Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions |
CN102112143A (zh) | 2008-07-30 | 2011-06-29 | 雀巢产品技术援助有限公司 | 预防、减少或治疗由缺血和类缺血病症引起的损害的方法和组合物 |
-
2010
- 2010-09-02 RU RU2012114057/15A patent/RU2569743C2/ru not_active IP Right Cessation
- 2010-09-02 EP EP10815735.5A patent/EP2464350B1/en not_active Not-in-force
- 2010-09-02 AU AU2010293065A patent/AU2010293065B2/en not_active Ceased
- 2010-09-02 WO PCT/US2010/002440 patent/WO2011031304A2/en active Application Filing
- 2010-09-02 CA CA2773523A patent/CA2773523A1/en not_active Abandoned
- 2010-09-02 JP JP2012528790A patent/JP5863656B2/ja not_active Expired - Fee Related
- 2010-09-02 ES ES10815735.5T patent/ES2593880T3/es active Active
- 2010-09-02 CN CN201080050618.9A patent/CN103533933A/zh active Pending
- 2010-09-02 MX MX2012002996A patent/MX2012002996A/es active IP Right Grant
- 2010-09-02 US US13/395,033 patent/US20120171303A1/en not_active Abandoned
- 2010-09-02 BR BR112012005540A patent/BR112012005540A2/pt not_active IP Right Cessation
-
2012
- 2012-04-10 ZA ZA2012/02561A patent/ZA201202561B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013510076A5 (ja) | ||
WO2016210372A3 (en) | Methods to treat neurological diseases | |
JP2014141525A5 (ja) | ||
WO2016042163A3 (en) | Ophthalmic drug compositions | |
EA021275B9 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания | |
ECSP15002815A (es) | Metodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estanina | |
WO2010129138A3 (en) | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment | |
WO2015092020A3 (en) | Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine | |
JP2015519329A5 (ja) | ||
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
JP2012180381A5 (ja) | ||
BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
FI3347002T3 (fi) | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa | |
WO2012023623A3 (ja) | ハンター症候群の治療剤 | |
WO2012038512A3 (en) | Composition comprising sod, lutein and zeaxanthin | |
Xiong et al. | Maternal separation exaggerates spontaneous recovery of extinguished contextual fear in adult female rats | |
RU2012114057A (ru) | Композиции и способы усиления когнитивной функции и связанных с ней функций у животных | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
PH12015502093A1 (en) | Antiemetic extended release solid dosage forms | |
BR112012020377A2 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
JP2012532197A5 (ja) | ||
JP2013520447A5 (ja) | ||
CO6180495A2 (es) | Formulacion de medicamento liquida |